Tradestie Institutional Equity Comparison Engine
NUVB vs CVAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CVAC Overall Edge
CVAC Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CureVac N.V. Ordinary Shares (CVAC) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus CVAC at 5.2x Forward P/E and 573.0% operating margin (-89.0% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against CVAC sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVAC
NUVB N/M vs CVAC 5.2x Fwd P/E
Growth & Margin Winner
CVAC
Op Margin -61.2% vs 573.0% ยท YoY +242.6% vs -89.0%
Momentum & Technical Winner
CVAC
1Y -46.9% vs +36.7% ยท 52W Pos 2% vs 67%
Options & Structure Winner
CVAC
BREAKDOWN (26th %ile IV) vs UNCLASSIFIED (100th %ile IV)
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
CVAC
NASDAQ
CureVac N.V. Ordinary Shares
Pharmaceutical Preparations
$4.66
-0.21% 1D
Market Cap
$1.1B
1M Return
-9.95%
1Y Return
+36.66%
Forward P/E
5.2x
Unified AI Score
60.2 / 100
BUY
Tech 60.0
Fund 56.0
Flow 50.0
Mom 58.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NUVB -46.85%
CVAC +36.66%
Spread: +30.87 pp (NUVB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NUVB TTM Op. Margin: -61.2%
CVAC TTM Op. Margin: 573.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NUVB vs CVAC. Trailing 12-month operating profitability (NUVB -61.2% vs CVAC 573.0%) and valuation multiples (NUVB N/M vs CVAC 5.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NUVB | CVAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.3B | $1.1B | Larger Scale | NUVB |
| Trailing P/E Ratio Valuation | N/M | 7.0x | Lower Multiple | CVAC |
| Forward P/E Ratio Valuation | N/M | 5.2x | Lower Multiple | CVAC |
| Revenue Growth (YoY) Growth | +242.6% | -89.0% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | -61.2% | 573.0% | Higher Margin | CVAC |
| Net Profit Margin Profitability | -67.4% | 182.1% | Higher Margin | CVAC |
| Return on Equity (ROE) Capital Efficiency | -49.1% | 40.2% | Higher ROE | CVAC |
| 52-Week Range Position Momentum | 2% ($4โ$10) | 67% ($2โ$6) | Stronger Trend | CVAC |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 55% Vol | 1.20ฮฒ ยท 62% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 61.0 / 100 (BUY) | 60.2 / 100 (BUY) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NUVB vs CVAC Buy Guide
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
CVAC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NUVB nor CVAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.